REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

03/04/2019 10:00

RNS Number : 9870U
AstraZeneca PLC
03 April 2019
 


03 April 2019 10:00 BST
 
Transactions by Persons Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
 
AstraZeneca PLC (the Company) announces that, on 29 March 2019, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP).
 
The AZDBP award was granted on 24 March 2016, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2015 performance into Ordinary Shares, and vested on completion of the three-year holding period.
 
Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below:
 




PDMR


Ordinary Shares acquired under the AZDBP




Pascal Soriot


15,755




Marc Dunoyer


4,838




 
For tax purposes, the fair market value of an Ordinary Share at vest was 6496 pence, being the closing price on the last trading day preceding the vesting.
 
Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.
 
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
 
 




Media Relations


 


 




Gonzalo Viña


UK/Global


+44 203 749 5916




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Jennifer Hursit


UK/Global


+44 203 749 5762




Christina M Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677




 


 


 




Investor Relations


 


 




Thomas Kudsk Larsen


 


+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharma - Cardiovascular; Metabolism


+44 203 749 5711




Nick Stone


BioPharma - Respiratory; Renal


+44 203 749 5716




Josie Afolabi


Other


+44 203 749 5631




Craig Marks


Finance; Fixed Income


+44 7881 615 764




Jennifer Kretzmann


Retail Investors; Corporate Access


+44 203 749 5824




US toll-free


 


+1 866 381 72 77




 
Adrian Kemp

Company Secretary
AstraZeneca PLC
 
 
 




1
 


Details of the person discharging managerial responsibilities / person closely associated




a)
 


Name


Pascal Soriot




2
 


Reason for the notification
 




a)
 


Position/status
 


Chief Executive Officer




b)
 


Initial notification /Amendment


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)
 


Name


AstraZeneca PLC




b)
 


LEI


PY6ZZQWO2IZFZC3IOL08




4i
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 




b)
 


Nature of the transaction
 
 


Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration.




c)
 


Price(s) and volume(s)
 


 




Price(s)


Volume(s)




0


15,755




 




d)
 


Aggregated information
 
- Aggregated volume
- Price


Not applicable - single transaction
 
 
 
 




e)
 


Date of the transaction
 


29 March 2019




f)
 


Place of the transaction
 


Outside a trading venue




 
 




1
 


Details of the person discharging managerial responsibilities / person closely associated




a)
 


Name


Marc Dunoyer




2
 


Reason for the notification
 




a)
 


Position/status
 


Chief Financial Officer




b)
 


Initial notification /Amendment


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)
 


Name


AstraZeneca PLC




b)
 


LEI


PY6ZZQWO2IZFZC3IOL08




4i
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument
 
Identification code


Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 




b)
 


Nature of the transaction
 
 


Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration.




c)
 


Price(s) and volume(s)
 


 




Price(s)


Volume(s)




0


4,838




 




d)
 


Aggregated information
 
- Aggregated volume
- Price


Not applicable - single transaction
 
 
 
 




e)
 


Date of the transaction
 


29 March 2019




f)
 


Place of the transaction
 


Outside a trading venue




 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHUOSWRKRASRRR